CR20110340A - Compuestos purina - Google Patents

Compuestos purina

Info

Publication number
CR20110340A
CR20110340A CR20110340A CR20110340A CR20110340A CR 20110340 A CR20110340 A CR 20110340A CR 20110340 A CR20110340 A CR 20110340A CR 20110340 A CR20110340 A CR 20110340A CR 20110340 A CR20110340 A CR 20110340A
Authority
CR
Costa Rica
Prior art keywords
purine compounds
purine
compounds
pain
compound
Prior art date
Application number
CR20110340A
Other languages
English (en)
Spanish (es)
Inventor
Charles Astles Peter
Guidetti Rossella
Patrick Hollinshead Sean
Wade Tidwell Michael
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20110340A publication Critical patent/CR20110340A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CR20110340A 2008-12-18 2011-06-17 Compuestos purina CR20110340A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13858908P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
CR20110340A true CR20110340A (es) 2011-09-16

Family

ID=41719189

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110340A CR20110340A (es) 2008-12-18 2011-06-17 Compuestos purina

Country Status (29)

Country Link
US (1) US8252798B2 (https=)
EP (1) EP2379555B1 (https=)
JP (1) JP5559812B2 (https=)
KR (1) KR101319630B1 (https=)
CN (1) CN102256977B (https=)
AR (1) AR075104A1 (https=)
AU (1) AU2009335997B2 (https=)
BR (1) BRPI0923195A2 (https=)
CA (1) CA2746740C (https=)
CL (1) CL2011001464A1 (https=)
CO (1) CO6390101A2 (https=)
CR (1) CR20110340A (https=)
DO (1) DOP2011000196A (https=)
EA (1) EA018386B1 (https=)
EC (1) ECSP11011151A (https=)
ES (1) ES2536880T3 (https=)
HN (1) HN2011001700A (https=)
IL (1) IL213167A (https=)
MA (1) MA32904B1 (https=)
MX (1) MX2011006442A (https=)
NZ (1) NZ593088A (https=)
PA (1) PA8851501A1 (https=)
PE (1) PE20110999A1 (https=)
SG (1) SG172253A1 (https=)
TN (1) TN2011000291A1 (https=)
TW (1) TWI376378B (https=)
UA (1) UA104010C2 (https=)
WO (1) WO2010080306A1 (https=)
ZA (1) ZA201103943B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2665277T3 (es) * 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
CA2770866C (en) 2009-08-28 2017-10-10 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CA2793024A1 (en) * 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
US8710063B2 (en) 2010-03-31 2014-04-29 Eli Lilly And Company Purine compounds used as CB2 agonists
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
MX2013003019A (es) 2010-09-15 2013-05-28 Hoffmann La Roche Compuestos de azabenzotiazol, composiciones y metodos de uso.
MX2013005445A (es) 2010-11-19 2013-07-29 Hoffmann La Roche Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
US9458136B2 (en) 2011-02-25 2016-10-04 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
JP2014526538A (ja) * 2011-09-20 2014-10-06 エフ．ホフマン−ラ ロシュ アーゲー イミダゾピリジン化合物、組成物及び使用方法
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
PE20151140A1 (es) * 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2014177527A1 (en) * 2013-05-02 2014-11-06 F. Hoffmann-La Roche Ag Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017052394A1 (en) * 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
WO2017181317A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2018137176A1 (en) * 2017-01-25 2018-08-02 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2017184412A1 (en) 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis
CA3036382A1 (en) * 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
EP3621619B1 (en) 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
CN118946565A (zh) * 2022-07-21 2024-11-12 长春金赛药业有限责任公司 取代的稠环大麻素受体化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
AU2002336462A1 (en) 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2005067546A2 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CN101044143A (zh) * 2004-10-22 2007-09-26 辉瑞产品公司 制备嘌呤化合物的方法
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
EA024006B1 (ru) * 2006-02-02 2016-08-31 Миллениум Фармасьютикалз, Инк. Ингибиторы е1 активирующих ферментов
WO2011066211A1 (en) * 2009-11-24 2011-06-03 Glaxosmithkline Llc Azabenzimidazoles as fatty acid synthase inhibitors
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor

Also Published As

Publication number Publication date
WO2010080306A1 (en) 2010-07-15
ECSP11011151A (es) 2011-07-29
SG172253A1 (en) 2011-07-28
TW201024296A (en) 2010-07-01
EA018386B1 (ru) 2013-07-30
BRPI0923195A2 (pt) 2016-02-16
CA2746740C (en) 2014-01-14
TWI376378B (en) 2012-11-11
PE20110999A1 (es) 2012-01-16
NZ593088A (en) 2012-12-21
IL213167A0 (en) 2011-07-31
CO6390101A2 (es) 2012-02-29
CN102256977A (zh) 2011-11-23
US20100160288A1 (en) 2010-06-24
PA8851501A1 (es) 2010-07-27
EA201170832A1 (ru) 2011-12-30
EP2379555A1 (en) 2011-10-26
UA104010C2 (en) 2013-12-25
KR20110084459A (ko) 2011-07-22
CN102256977B (zh) 2014-04-16
ES2536880T3 (es) 2015-05-29
CA2746740A1 (en) 2010-07-15
ZA201103943B (en) 2012-11-28
AR075104A1 (es) 2011-03-09
MA32904B1 (fr) 2011-12-01
EP2379555B1 (en) 2015-02-25
MX2011006442A (es) 2011-07-19
AU2009335997A1 (en) 2011-06-23
IL213167A (en) 2013-11-28
DOP2011000196A (es) 2011-10-31
JP5559812B2 (ja) 2014-07-23
US8252798B2 (en) 2012-08-28
KR101319630B1 (ko) 2013-10-17
HN2011001700A (es) 2013-05-06
AU2009335997B2 (en) 2012-05-10
CL2011001464A1 (es) 2012-01-20
JP2012512873A (ja) 2012-06-07
TN2011000291A1 (en) 2012-12-17

Similar Documents

Publication Publication Date Title
DOP2011000196A (es) Compuestos purina
UY31065A1 (es) Heterociclos ciclicos
EA201100037A1 (ru) Органические соединения
MX357820B (es) Composiciones para uso en la manufactura de medicamentos para tratamiento de esclerosis multiple progresiva.
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
CY1111793T1 (el) Μυκητοκτονες συνθεσεις
NI200900081A (es) Peptidommético smac útiles como inhibidores de iap
CL2009000542A1 (es) Uso de un antagonista de c-met y egfr de formula general i para preparar un medicamento para tratar el cancer.
DOP2012000006A (es) Agonista de gpr119
CR20130023A (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2008003041A1 (es) Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
GT200600117A (es) Nuevos compuestos farmaceuticos
BR112012024586A2 (pt) compostos de purina
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
UY33348A (es) Compuestos de furopiridina y usos de los mismos
EP2114418A4 (en) ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN
CO6382113A2 (es) Compuestos quimicos
CR20110332A (es) Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida
CR20110342A (es) Compuestos ciclopropilo
CL2009001493A1 (es) Compuestos derivados de 3-cianopirrolidin-fenil-oxazolidinonas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de infecciones bacterianas.